Search
Umbralisib
go.drugbank.com/drugs/DB14989ApprovedInvestigationalWithdrawn[A229363] Follicular lymphoma is also treated with rituximab and other chemotherapeutic agents, but may show similar progression. … It was marketed as Ukoniq by TG Therapeutics and has been approved for the treatment of relapsing and refractory marginal cell lymphoma and follicular lymphoma in adults.
Propiverine
go.drugbank.com/drugs/DB12278ApprovedOveractive bladder (OAB) is a chronic condition of the lower urinary tract characterized by urinary urgency, increased frequency of urination, and nocturia (frequent waking during the night to urinate)
Pegulicianine
go.drugbank.com/drugs/DB18731ApprovedInvestigational[L50537] Pegulicianine (under the brand name Lumisight) was approved for use by the FDA in April 2024.[L50537,L50547] It received Fast Track and priority review for this indication.[L50547]
Bordetella pertussis toxoid antigen (formaldehyde, glutaraldehyde inactivated)
go.drugbank.com/drugs/DB10991ApprovedInvestigationalBordetella pertussis toxoid antigen (formaldehyde, glutaraldehyde inactivated) is a vaccine that is used in the prophylaxis of Pertussis (whooping cough), which is caused by a small Gram-negative coccobacillus
Histrelin
go.drugbank.com/drugs/DB06788ApprovedInvestigationalWithdrawn[L41715] Vantas was later discontinued by Endo Pharmaceuticals Inc. on September 21, 2021. … [L41715] The Vantas product was approved by the FDA in October 2004 for the palliative treatment of this condition.
Etonogestrel
go.drugbank.com/drugs/DB00294ApprovedInvestigational[A37184] The first product including etonogestrel was developed by the Merck subsidiary Organon and FDA approved in 2001.[L5692]
Ropinirole
go.drugbank.com/drugs/DB00268ApprovedInvestigationalIt is manufactured by GlaxoSmithKline Pharmaceuticals. Ropinirole was initially approved in 1997 by the FDA [FDA label] for the management of Parkinson's disease.
Human papillomavirus type 11 L1 capsid protein antigen
go.drugbank.com/drugs/DB10300ApprovedInvestigationalIt is an immunization for young men and women 9-26 years of age for the prevention of diseases caused by Human Papillomavirus (HPV) types 6, 11, 16 and 18. … The vaccine is prepared from the purified virus-like particles (VLPs) of the major capsid (L1) protein of HPV Types 6, 11, 16, and 18, which are produced by separate fermentations in recombinant *Saccharomyces
Human papillomavirus type 16 L1 capsid protein antigen
go.drugbank.com/drugs/DB10301ApprovedInvestigationalIt is an immunization for young men and women 9-26 years of age for the prevention of diseases caused by Human Papillomavirus (HPV) types 6, 11, 16 and 18. … The vaccine is prepared from the purified virus-like particles (VLPs) of the major capsid (L1) protein of HPV Types 6, 11, 16, and 18, which are produced by separate fermentations in recombinant *Saccharomyces
Human papillomavirus type 18 L1 capsid protein antigen
go.drugbank.com/drugs/DB10302ApprovedInvestigationalIt is an immunization for young men and women 9-26 years of age for the prevention of diseases caused by Human Papillomavirus (HPV) types 6, 11, 16 and 18. … The vaccine is prepared from the purified virus-like particles (VLPs) of the major capsid (L1) protein of HPV Types 6, 11, 16, and 18, which are produced by separate fermentations in recombinant *Saccharomyces